AAM said the report highlights that 90% of the brand biologics scheduled to lose exclusivity in the next 10 years do not have biosimilars in development.
AAM submitted comments to CMS, highlighting the extent and ways in which Part D sponsors and their PBMs engage in practices that favor, intentionally or unintentionally, more expensive reference drugs and biological products over generics.
AAM said that by including drugs with generics and biosimilars in development in the 15 drugs selected for negotiation, CMS highlights a central flaw in the IRA price setting scheme.
The proposed FOP nutrition label provides information on saturated fat, sodium and added sugars content showing whether the food has “Low,” “Med” or “High” levels of these nutrients.
Generic Xifaxin is indicated for the reduction in risk of overt hepatic encephalopathy recurrence in adults and irritable bowel syndrome with diarrhea.
